Composition for Oral or Nasal Delivery of Tetanus, Diphtheria, and Pertussis Vaccine alone or in combination using Neurotoxin Associated Proteins
US-2024131137-A1 · Apr 25, 2024 · US
Compositions comprising recombinant probiotic bacteria and methods of use thereof
US10583186B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10583186-B2 |
| Application number | US-201615545462-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 22, 2016 |
| Priority date | Jan 23, 2015 |
| Publication date | Mar 10, 2020 |
| Grant date | Mar 10, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention features probiotic bacteria expressing Clostridium difficile SlpA, or fragment thereof, and its use for the treatment or prevention of Clostridium difficile infection and gut colonization.
First claim
Opening claim text (preview).
What is claimed is: 1. An isolated polypeptide comprising, from the amino-terminus to the carboxy-terminus, a bacterial secretion signal, a C. difficile SlpA variable domain, and a Lactobacillus SlpA cell wall binding domain having the amino acid sequence SEQ ID NO:2. 2. The isolated polypeptide of claim 1 , wherein the SlpA variable domain has the amino acid sequence SEQ ID NO: 1. 3. The isolated polypeptide of claim 1 , wherein the bacterial secretion signal is a Lactococcus or Lactobacillus secretion signal. 4. The isolated polypeptide of claim 1 , wherein the bacterial secretion signal has the amino acid sequence SEQ ID NO: 3. 5. The isolated polypeptide of claim 1 , having the amino acid sequence SEQ ID NO: 4. 6. An isolated polypeptide comprising, from the amino-terminus to the carboxy-terminus, a bacterial secretion signal having the amino acid sequence SEQ ID NO: 3, a C. difficile SlpA variable domain, and a Lactobacillus SlpA cell wall binding domain. 7. The isolated polypeptide of claim 6 , wherein the SlpA variable domain has the amino acid sequence SEQ ID NO: 1. 8. The isolated polypeptide of claim 6 , wherein the SlpA cell wall binding domain is a Lactobacillus acidophilus or Lactobacillus casei SlpA cell wall binding domain. 9. The isolated polypeptide of claim 6 , wherein the Lactobacillus SlpA cell wall binding domain has the amino acid sequence SEQ ID NO: 2. 10. The isolated polypeptide of claim 6 , having the amino acid sequence SEQ ID NO: 4. 11. An isolated polypeptide comprising, from the amino-terminus to the carboxy-terminus, a bacterial secretion signal, a C. difficile SlpA variable domain, and a Lactobacillus SlpA cell wall binding domain, wherein the isolated polypeptide has the amino acid sequence SEQ ID NO: 4. 12. The isolated polypeptide of claim 3 , wherein the bacterial secretion signal is a Lactobacillus acidophilus or Lactobacillus casei secretion signal.
Assignees
Inventors
Classifications
Antibacterial agents · CPC title
expressing foreign proteins · CPC title
- A61K39/08Primary
Clostridium, e.g. Clostridium tetani · CPC title
Lactobacilli, e.g. L. acidophilus or L. brevis · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10583186B2 cover?
- The invention features probiotic bacteria expressing Clostridium difficile SlpA, or fragment thereof, and its use for the treatment or prevention of Clostridium difficile infection and gut colonization.
- Who is the assignee on this patent?
- Univ Arizona, Us Veterans Affairs
- What technology area does this patent fall under?
- Primary CPC classification A61K39/08. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).